The next generation biopharmaceuticals
Press & News
Board of Directors
Håkan Åström, Med. Dr. h.c. Chairman
Dr. Åström is a board member of PledPharma AB (Chairman), Tubulus RP Förvaltning AB (Chairman), MedCore Sweden AB (Chairman), Rhenman & Partners Asset Management AB, and Ferrosan Medical Devices AS. Dr. Åström was formerly CEO of Kabi Pharmacia and Senior Vice President of Pharmacia Corporation.
Mathias Uhlén, Ph.D. Deputy Chairman
Prof. Uhlén is a co-founder of Affibody AB, and Professor of Biotechnology at the Royal Institute of Technology in Stockholm. He is a Program Director of the Swedish Human Protein (HPA) program, funded by the Knut and Alice Wallenberg foundation, and a Board member of Atlas Antibodies AB (Chairman), Antibodypedia AB (Chairman), Bure AB, Novozymes AS, Atlasab Intressenter AB and SweTree Technologies AB.
Jonathan Knowles, Prof., Ph.D. Director
Jonathan Knowles is currently professor in personalized health care at the Finnish Institute for Molecular Medicine at the University of Helsinki, and visiting chair at the University of Oxford. He also serves on the board of a number of biotech companies including Immunocore Ltd. (Chairman), Adaptimmune Ltd (Chairman) and Caris Life Sciences. In his most recent executive role he was president of group research at Roche and member of Roche’s Corporate Executive Committee. Dr Knowles was also a member of the Genentech Board for 12 years and a member of the Chugai Board for seven years.
Jakob Lindberg, Med. Lic. Director
Jakob Lindberg is CEO of Oncopeptides AB and board member of Atlas Antibodies AB och Alligator Bioscience AB. Mr. Lindberg holds a Med. Lic. in Molecular Immunology a MSc in pre-clinical medicine from the Karolinska Institutet in Sweden and a BA in Finance and Administration from the Stockholm University. He started his career as an analyst with Merrill Lynch in London and moved to consultancy with McKinsey in Stockholm, followed by a period in Gothenburg as CEO and co-founder of Cellectricon AB.
Affibodys latest Press releases
Affibody in short
Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
Upcoming reports Financial calendar
- Year-end report (February 24, 2017)